The FDA has declined to approve glatiramer acetate (GA) depot in the treatment of relapsing types of multiple sclerosis (MS), issuing a complete response letter (CRL) for the long-acting, injectable form of GA.
The FDA has issued a complete response letter (CRL) for glatiramer acetate (GA) depot for the treatment of patients with forms of relapsing multiple sclerosis (MS).1 GA depot is an injectable, once-a-month, long-acting form of GA developed by Viatris and Mapi Pharma, and the application was for the approval of GA depot at a dosage of 40 mg.2 Next steps will be determined as each company reviews the CRL.1
The new drug application filing for GA depot was supported by results from a phase 3, multinational, placebo-controlled, double-blind clinical trial (NCT04121221).3 The study separated 1106 participants into 2 cohorts, either receiving a placebo or GA depot at a dose of 40 mg. Patients underwent a total of 13 intramuscular injections over 52 weeks: 1 every 4 weeks. Included participants had recorded at least 1 relapse in the previous year.
This intervention significantly reduced the rate of annual relapses by over 30% compared with placebo (P = .0066) and, additionally, created a more favorable schedule for patients who also experienced less reactions at the injection site compared with other GA medications.
An estimated 1 million people in the US are living with MS, more than doubling previous estimations, according to the National Multiple Sclerosis Society. Among those with MS, around 85% are initially diagnosed with relapsing MS, indicating the need for interventions such as GA depot.
At present, GA depot is also being evaluated in a phase 2 trial (NCT03362294) focused on patients with primary progressive MS.4 One-year data were previously presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting, with results suggesting a favorable efficacy and safety profile as patients demonstrated stable Expanded Disability Status Scale scores and experienced infrequent adverse events.5 Just over 69% of those treated with GA Depot were observably progression-free after 12 months.
References
1. US FDA declines to approve Viatris's injection for multiple sclerosis. Reuters. March 11, 2024. Accessed March 11, 2024. https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-viatriss-injection-multiple-sclerosis-2024-03-11/
2. FDA sets PDUFA date for monthly MS drug. Formulary Watch. August 8, 2023. Accessed March 11, 2024. https://www.formularywatch.com/view/fda-sets-pdufa-date-for-monthly-ms-drug
3. Viatris and Mapi Pharma announce FDA acceptance of new drug application filing for GA depot for the treatment of relapsing forms of multiple sclerosis. News release. Viatris. August 7, 2023. Accessed March 11, 2024. https://newsroom.viatris.com/2023-08-07-Viatris-and-Mapi-Pharma-Announce-FDA-Acceptance-of-New-Drug-Application-Filing-for-GA-Depot-for-the-Treatment-of-Relapsing-Forms-of-Multiple-Sclerosis
4. Safety and efficacy of monthly long-acting IM injection of 25mg or 40 mg GA depot in subjects with PPMS. ClinicalTrials.gov. Updated November 15, 2023. Accessed March 11, 2024. https://clinicaltrials.gov/study/NCT03362294
5. Fletcher S, Kimelman NB, Danon U, et al. Glatiramer acetate depot (extended release) phase 2a study in patients with primary progressive multiple sclerosis: safety and efficacy 1 year interim snapshot analysis. Presented at: CMSC Annual Meeting; June 1-4, 2022; National Harbor, MD. Poster 8374.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Challenges in developing next-generation cancer therapies persist; research indicates widespread utilization and hurdles in affordability and access to glucagon-like peptide-1 (GLP-1) medications; legislation seeks to legalize therapeutic use of psychedelics in California.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Health Equity and Access Weekly Roundup: May 11, 2024
May 11th 2024This week's topics include frameworks for improving health equity nationwide, addressing social determinants of health, discussing CMS's Medicare rules, investigating breast cancer treatment refusal, and exploring HIV and major depressive disorder in underrepresented groups.
Read More